Supported by the National Institutes of Health Grants R01EY023591, P30EY002162, and T32EY007043; Foundation Fighting Blindness; Research to Prevent Blindness RP Nelson Trust Award and Unrestricted funds; Claire Giannini Foundation; That Man May See, Inc.; and the Minnie Flaura Turner Memorial Fund for Impaired Vision Research Award.
Disclosure: K.G. Foote, Carl Zeiss Meditec, Inc. (E); J.J. Wong, None; A.E. Boehm, None; E. Bensinger, C. Light Technologies (C); T.C. Porco, None; A. Roorda, USPTO#7,118,216, USPTO#6,890,076 (University of Rochester, University of Houston [P]), C. Light Technologies (I); J.L. Duncan, Vedere Bio (C), 4D Therapeutics (C), Applied Genetics Technology Corporation (C), California Institute for Regenerative Medicine (C), Editas Medicine (C), Eloxx (C), Foundation Fighting Blindness (C), Biogen/Nightstar Therapeutics (C), ProQR Therapeutics (C), SparingVision (C), Spark Therapeutics (C)